Biotech Values

[DewDiligence]

SBTX slashes pipeline and workforce (27% layoff):

https://www.businesswire.com/news/home/20220331005874/en/Silverback-Therapeutics-Updates-Strategic-Priorities-and-Reports-Fourth-Quarter-and-Full-Year-2021-Financial-Results

“Upon comprehensive review of our clinical and preclinical data for our TLR8 oncology programs, we have made the decision to discontinue the development of SBT6050 and SBT6290, and focus our resources on SBT8230 for chronic HBV as well as our ImmunoTAC discovery programs,” said Laura Shawver, Ph.D., chief executive officer of Silverback.

SBT8230 is a TLR8 (I-O) agent conjugated to an ASGR1 “targeted” mAb. The SBT8230 HBV program is a very long longshot, IMHO.

STBX is down 83% from its IPO only 16 months ago (#msg-159913427).